Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-051 vs Perjeta in HER2-positive Metastatic Breast Cancer
NCT07386938Phase 3Active, not recruiting
- Sponsor
- R-Pharm
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of RPH-051 in breast cancer, sponsored by R-Pharm. Started Aug 2024; status: active, not recruiting.
02
Drugs
RPH-051
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07386938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07386938.